Search results for: “50”

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017) Updates since publication: January 2024 update (edited March 2024): Recently, individual patients have been reported (PMID 38129972) to carry only one of the two SNPs in the HapB3 haplotype (i.e., c.1236G>A without c.1129-5923C>G), suggesting…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018) Updates since publication: March 2024: At the time of guideline publication, the extent of dosage reduction for thiopurines recommended for patients with intermediate metabolism for both TPMT and NUDT15 was unclear. A recent publication…

The following is a list of PGx implementers who are using CPIC guidelines as part of a program to facilitate use of genetic tests to guide prescribing for patients in clinical care settings: Institution Website and/or Contact (if available) AIG Hospitals, Hyderabad, India AIG Hospitals Allina Health Christine Kroger; Christine.Kroger@allina.com Arkansas Children’s Hospital Arkansas Children’s…

What is CPIC? The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for…